- Home
- BMRA vs XXII Comparison
BMRA vs XXII Comparison
Compare BMRA & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRA | XXII |
|---|---|---|
| Founded | 1971 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BMRA | XXII |
|---|---|---|
| Price | $2.66 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 149.2K | ★ 156.0K |
| Earning Date | 01-14-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,457,000.00 | ★ $20,346,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $79.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.98 |
| 52 Week Low | $2.11 | $0.75 |
| 52 Week High | $10.16 | $216.66 |
Technical Indicators
Market Signals| Indicator | BMRA | XXII |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 42.51 |
| Support Level | $2.56 | $0.81 |
| Resistance Level | $2.79 | $0.89 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 42.02 | 36.63 |
Price Performance
Historical ComparisonAbout BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.